Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)

China flag China · Delayed Price · Currency is CNY
94.20
+2.13 (2.31%)
Apr 29, 2026, 2:25 PM CST
10.39%
Market Cap 41.43B
Revenue (ttm) 5.67B
Net Income (ttm) 2.41B
Shares Out 450.00M
EPS (ttm) 5.36
PE Ratio 17.17
Forward PE 15.66
Dividend 1.20 (1.30%)
Ex-Dividend Date n/a
Volume 4,736,100
Average Volume 5,184,854
Open 91.99
Previous Close 92.07
Day's Range 91.88 - 95.39
52-Week Range 80.53 - 122.20
Beta 0.27
RSI 42.48
Earnings Date Apr 23, 2026

About SHA:688578

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company’s lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 1,823
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688578
Full Company Profile

Financial Performance

In 2025, SHA:688578's revenue was 5.19 billion, an increase of 45.80% compared to the previous year's 3.56 billion. Earnings were 2.19 billion, an increase of 53.10%.

Financial Statements

News

There is no news available yet.